285 related articles for article (PubMed ID: 23774991)
21. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
Allison KH; Kandalaft PL; Sitlani CM; Dintzis SM; Gown AM
Breast Cancer Res Treat; 2012 Jan; 131(2):413-24. PubMed ID: 21369717
[TBL] [Abstract][Full Text] [Related]
22. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
23. Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.
Markopoulos C; Xepapadakis G; Venizelos V; Tsiftsoglou A; Misitzis J; Panoussis D; Antonopoulou Z; Stathoulopoulou M; Zobolas V; Gogas H
Eur J Surg Oncol; 2012 May; 38(5):413-9. PubMed ID: 22425282
[TBL] [Abstract][Full Text] [Related]
24. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.
Ademuyiwa FO; Thorat MA; Jain RK; Nakshatri H; Badve S
Mod Pathol; 2010 Feb; 23(2):270-5. PubMed ID: 19946260
[TBL] [Abstract][Full Text] [Related]
25. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
[TBL] [Abstract][Full Text] [Related]
26. [Clinicopathological features, prognosis and influence in the adjuvant treatment of the risk recurrence groups determined by the 21 gene expression profile, Oncotype Dx®, in early breast cancer].
Gerson Cwilich R; Alban de la Torre LF; Villalobos Prieto A; Serrano Olvera JA
Gac Med Mex; 2012; 148(2):117-24. PubMed ID: 22622310
[TBL] [Abstract][Full Text] [Related]
27. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer.
Yang PS; Lee YH; Chung CF; Chang YC; Wang MY; Lo C; Tsai LW; Shih KH; Lei J; Yu BL; Cheng SH; Huang CS
Jpn J Clin Oncol; 2019 Dec; 49(11):1029-1036. PubMed ID: 31287883
[TBL] [Abstract][Full Text] [Related]
28. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT
Schildgen V; Warm M; Brockmann M; Schildgen O
Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145
[TBL] [Abstract][Full Text] [Related]
29. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Turner BM; Skinner KA; Tang P; Jackson MC; Soukiazian N; Shayne M; Huston A; Ling M; Hicks DG
Mod Pathol; 2015 Jul; 28(7):921-31. PubMed ID: 25932962
[TBL] [Abstract][Full Text] [Related]
30. The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting.
Choi JDW; Hughes TMD; Marx G; Boyages J; Rutovitz J; Hasovits C; Parasyn A; Edirimanne S; Ngui NK
Breast J; 2022; 2022():1199245. PubMed ID: 35711899
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer.
Cotter MB; Dakin A; Maguire A; Walshe JM; Kennedy MJ; Dunne B; Riain CÓ; Quinn CM
Virchows Arch; 2017 Sep; 471(3):321-328. PubMed ID: 28707056
[TBL] [Abstract][Full Text] [Related]
32. Copy number profiling of Oncotype DX genes reveals association with survival of breast cancer patients.
Ahmed W; Malik MFA; Saeed M; Haq F
Mol Biol Rep; 2018 Dec; 45(6):2185-2192. PubMed ID: 30225582
[TBL] [Abstract][Full Text] [Related]
33. Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer.
Gyanchandani R; Lin Y; Lin HM; Cooper K; Normolle DP; Brufsky A; Fastuca M; Crosson W; Oesterreich S; Davidson NE; Bhargava R; Dabbs DJ; Lee AV
Clin Cancer Res; 2016 Nov; 22(21):5362-5369. PubMed ID: 27185370
[TBL] [Abstract][Full Text] [Related]
34. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
35. Applying new Magee equations for predicting the Oncotype Dx recurrence score.
Sughayer M; Alaaraj R; Alsughayer A
Breast Cancer; 2018 Sep; 25(5):597-604. PubMed ID: 29691722
[TBL] [Abstract][Full Text] [Related]
36. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
Lewin R; Sulkes A; Shochat T; Tsoref D; Rizel S; Liebermann N; Hendler D; Neiman V; Ben-Aharon I; Friedman E; Paluch-Shimon S; Margel D; Kedar I; Yerushalmi R
Breast Cancer Res Treat; 2016 Jun; 157(3):511-6. PubMed ID: 27225387
[TBL] [Abstract][Full Text] [Related]
37. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
Kelly CM; Krishnamurthy S; Bianchini G; Litton JK; Gonzalez-Angulo AM; Hortobagyi GN; Pusztai L
Cancer; 2010 Nov; 116(22):5161-7. PubMed ID: 20665886
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.
Remoué A; Conan-Charlet V; Deiana L; Tyulyandina A; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2021 Feb; 108():51-59. PubMed ID: 33245987
[TBL] [Abstract][Full Text] [Related]
39. Commercialized multigene predictors of clinical outcome for breast cancer.
Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
[TBL] [Abstract][Full Text] [Related]
40. 72-gene classifier for predicting prognosis of estrogen receptor-positive and node-negative breast cancer patients using formalin-fixed, paraffin-embedded tumor tissues.
Nishio M; Naoi Y; Tsunashima R; Nakauchi C; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Clin Breast Cancer; 2014 Jun; 14(3):e73-80. PubMed ID: 24461457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
